Send your comments and tips to email@example.com
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Nurse at small
Dr. Gwenn Is In
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Short White Coat blogger Jennifer Srygley
Tuesday, April 17, 2007
Today's Globe: Guidant, anemia drug, marathon medical tent, Frank Westheimer, FDA screening
The Food and Drug Administration has lifted a warning letter that had been hanging over the Guidant division of Boston Scientific Corp., the medical-device maker said yesterday, freeing the Natick company to introduce products that had been blocked by quality-control problems.
One in four cancer patients given Amgen Inc.'s Aranesp anemia drug in a study died after 19 weeks, a rate about 5 points higher than among those on a placebo, a finding likely to make doctors more cautious about the product.
Conditions during yesterday's Boston Marathon weren't as drastic as predicted -- the temperature was higher -- but the wind, rain, and cold combined to make it a challenging race for medical personnel (left), who had prepared for the worst.
Retired Harvard University professor Frank H. Westheimer, a major force in 20th century chemistry who served as a science adviser to President Lyndon Johnson, died Saturday of natural causes at his home in Cambridge, relatives said yesterday. He was 95.
Senator Edward M. Kennedy is leading efforts in Congress to pass legislation to overhaul the Food and Drug Administration. Such reform is needed, but the proposed legislation is so weak that it is unlikely to save any lives, write Judy Norsigian, executive director of Our Bodies Ourselves, and Diana Zuckerman, president of the National Research Center for Women & Families, in an opinion piece.
An FDA proposal to ban anyone with a financial interest of $50,000 or greater from taking part in an FDA advisory panel is a vain political effort to placate the medical journal editors, ethicists, and bureaucrats who enforce conflict-of-interest regulations, writes Dr. Thomas P. Stossel of Harvard Medical School and Brigham & Women's Hospital on the op-ed page.